NSC348884
(Synonyms: N1,N1,N2,N2-四[(6-甲基-1H-苯并咪唑-2-基)甲基]-1,2-乙二胺) 目录号 : GC16151A nucleophosmin inhibitor
Cas No.:81624-55-7
Sample solution is provided at 25 µL, 10mM.
Quality Control & SDS
- View current batch:
- Purity: >98.00%
- COA (Certificate Of Analysis)
- SDS (Safety Data Sheet)
- Datasheet
IC50: 1.7-4.0 μM for tested cancer cell lines
NSC348884 is a nucleophosmin inhibitor.
Nucleophosmin is identified as a multifunctional nucleolar phosphoprotein, which is dysregulated in human malignancies resulting in anti-apoptosis and differentiation inhibition.
In vitro: NSC348884, which was identified as a putative nucleophosmin small molecular inhibitor, was found to be able to disrupt a hydrophobic pocket that was required for oligomerization, and NSC348884 could also inhibit the cell proliferation in distinct cancer cell lines and disrupt nucleophosmin oligomer formation. Moreover, the treatment of several cancer cell types with NSC348884 could dose-dependently upregulate p53 and also induce apoptosis that correlated with H2AX phosphorylation, poly(ADP-ribose) polymerase cleavage as well as Annexin V. Furthermore, NSC348884 could also synergize doxorubicin cytotoxicity on the viability of cancer cells [1].
In vivo: Previous study showed that the in-vivo intravasation and invasion could be significantly inhibited after the injection of NSC348884 into the tumor-bearing mice. In addition, there was no significant difference in overall cell death that was observed by histology in the treated tumors with the 4-hour brief treatments, indicating that the inhibition seen was specific to migration [2].
Clinical trial: Up to now, NSC348884 is still in the preclinical development stage.
References:
[1] Qi W,Shakalya K,Stejskal A,Goldman A,Beeck S,Cooke L,Mahadevan D. NSC348884, a nucleophosmin inhibitor disrupts oligomer formation and induces apoptosis in human cancer cells. Oncogene.2008 Jul 10;27(30):4210-20.
[2] Patsialou A,Wang Y,Lin J,Whitney K,Goswami S,Kenny PA,Condeelis JS. Selective gene-expression profiling of migratory tumor cells in vivo predicts clinical outcome in breast cancer patients. Breast Cancer Res.2012 Oct 31;14(5):R139.
Cas No. | 81624-55-7 | SDF | |
别名 | N1,N1,N2,N2-四[(6-甲基-1H-苯并咪唑-2-基)甲基]-1,2-乙二胺 | ||
化学名 | N1,N1,N2,N2-tetrakis((6-methyl-1H-benzo[d]imidazol-2-yl)methyl)ethane-1,2-diamine | ||
Canonical SMILES | CC1=CC=C2N=C(CN(CC3=NC4=CC=C(C)C=C4N3)CCN(CC5=NC6=CC=C(C)C=C6N5)CC7=NC8=CC=C(C)C=C8N7)NC2=C1 | ||
分子式 | C38H40N10 | 分子量 | 636.79 |
溶解度 | ≥ 63.7mg/mL in DMSO | 储存条件 | Store at -20°C |
General tips | 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。 储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。 为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。 |
||
Shipping Condition | 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。 |
制备储备液 | |||
1 mg | 5 mg | 10 mg | |
1 mM | 1.5704 mL | 7.8519 mL | 15.7038 mL |
5 mM | 0.3141 mL | 1.5704 mL | 3.1408 mL |
10 mM | 0.157 mL | 0.7852 mL | 1.5704 mL |
第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量) | ||||||||||
给药剂量 | mg/kg | 动物平均体重 | g | 每只动物给药体积 | ul | 动物数量 | 只 | |||
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方) | ||||||||||
% DMSO % % Tween 80 % saline | ||||||||||
计算重置 |
计算结果:
工作液浓度: mg/ml;
DMSO母液配制方法: mg 药物溶于 μL DMSO溶液(母液浓度 mg/mL,
体内配方配制方法:取 μL DMSO母液,加入 μL PEG300,混匀澄清后加入μL Tween 80,混匀澄清后加入 μL saline,混匀澄清。
1. 首先保证母液是澄清的;
2.
一定要按照顺序依次将溶剂加入,进行下一步操作之前必须保证上一步操作得到的是澄清的溶液,可采用涡旋、超声或水浴加热等物理方法助溶。
3. 以上所有助溶剂都可在 GlpBio 网站选购。